Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Orphanet Journal of Rare Diseases
Published in: Orphanet Journal of Rare Diseases 1/2013

Open Access 01-12-2013 | Research

Prevalence of specific anti-skin autoantibodies in a cohort of patients with inherited epidermolysis bullosa

Authors: Marilina Tampoia, Domenico Bonamonte, Angela Filoni, Lucrezia Garofalo, Maria Grazia Morgese, Luigia Brunetti, Chiara Di Giorgio, Giuseppina Annicchiarico

Published in: Orphanet Journal of Rare Diseases | Issue 1/2013

Login to get access

Abstract

Background

Inherited epidermolysis bullosa (EB) is a group of skin diseases characterized by blistering of the skin and mucous membranes.
There are four major types of EB (EB simplex, junctional EB, dystrophic EB and Kindler syndrome) caused by different gene mutations. Dystrophic EB is derived from mutations in the type VII collagen gene (COL7A1), encoding a protein which is the predominant component of the anchoring fibrils at the dermal-epidermal junction.
For the first time in literature, we have evaluated the presence of anti-skin autoantibodies in a wider cohort of patients suffering from inherited EB and ascertained whether they may be a marker of disease activity.

Methods

Sera from patients with inherited EB, 17 with recessive dystrophic EB (RDEB), 10 with EB simplex (EBS) were analysed. As much as 20 patients with pemphigus vulgaris, 21 patients with bullous pemphigoid and 20 healthy subjects were used as controls.
Anti-skin autoantibodies were tested in all samples with the Indirect Immunofluorescence (IIF) method and the currently available ELISA method in order to detect anti-type VII collagen, anti-BP180 and anti-BP230 autoantibodies.

Results

The mean concentrations of anti-type VII collagen autoantibodies titres, anti-BP180 and anti-BP230 autoantibodies were statistically higher in RDEB patients than in EBS patients.
The sensitivity and specificity of the anti-type VII collagen ELISA test were 88.2% and 96.7%. The Birmingham Epidermolysis Bullosa Severity score, which is used to evaluate the severity of the disease, correlated with anti-skin autoantibodies titres.

Conclusions

The precise pathogenic role of circulating anti-skin autoantibodies in RDEB is unclear. There is a higher prevalence of both anti-type VII collagen and other autoantibodies in patients with RDEB, but their presence can be interpreted as an epiphenomenon.
Appendix
Available only for authorised users
Literature
1.
Fine JD, Eady RA, Bauer EA, Bauer JW, Bruckner-Tuderman L, Heagerty A, Hintner H, Hovnanian A, Jonkman MF, Leigh I, McGrath JA, Mellerio JE, Murrell DF, Shimizu H, Uitto J, Vahlquist A, Woodley D, Zambruno G: The classification of inherited epidermolysis bullosa (EB): report of the Third International Consensus Meeting on Diagnosis and Classification of EB. J Am Acad Dermatol. 2008, 58: 931-950. 10.1016/j.jaad.2008.02.004.PubMedCrossRef
2.
Fine JD: Inherited epidermolysis bullosa. Orphanet J Rare Dis. 2010, 28: 5-12.
3.
Uitto J, Richard G: Progress in epidermolysis bullosa: from eponyms to molecular genetic classification. Clin Dermatol. 2005, 23: 33-40. 10.1016/j.clindermatol.2004.09.015.PubMedCrossRef
4.
Shimizu H, Sato M, Ban M, Kitajima Y, Ishizaki S, Harada T, Bruckner-Tuderman L, Fine JD, Burgeson R, Kon A, McGrath JA, Christiano AM, Uitto J, Nishikawa T: Immunohistochemical, ultrastructural, and molecular features of Kindler syndrome distinguish it from dystrophic epidermolysis bullosa. Arch Dermatol. 1997, 133: 1111-1117. 10.1001/archderm.1997.03890450057007.PubMedCrossRef
5.
Has C: Molecular genetic assays for inherited epidermolysis bullosa. Clin Dermatol. 2011, 29: 420-426. 10.1016/j.clindermatol.2011.01.011.PubMedCrossRef
6.
Wertheim-Tysarowska K, Sobczyńska-Tomaszewska A, Kowalewski C, Skroński M, Swięćkowski G, Kutkowska-Kaźmierczak A, Woźniak K, Bal J: The COL7A1 mutation database. Hum Mutat. 2012, 33: 327-331. 10.1002/humu.21651.PubMedCrossRef
7.
Intong LR, Murrell DF: Inherited epidermolysis bullosa: new diagnostic criteria and classification. Clin Dermatol. 2012, 30: 70-77. 10.1016/j.clindermatol.2011.03.012.PubMedCrossRef
8.
Pohla-Gubo G, Cepeda-Valdes R, Hintner H: Immunofluorescence mapping for epidermolysis bullosa. Dermatol Clin. 2010, 28: 201-210. 10.1016/j.det.2009.12.005.PubMedCrossRef
9.
Yiasemides E, Walton J, Marr P, Villanueva EV, Murrell DF: A comparative study between transmission electron microscopy and immunofluorescence mapping in the diagnosis of epidermolysis bullosa. Am J Dermatopathol. 2006, 28: 387-394. 10.1097/01.dad.0000211510.44865.6d.PubMedCrossRef
10.
Uitto J, Christiano AM: Molecular basis for the dystrophic forms of epidermolysis bullosa: mutations in the type VII collagen gene. Arch Dermatol Res. 1994, 287: 16-22. 10.1007/BF00370713.PubMedCrossRef
11.
Christiano AM, Rosenbaum LM, Chung-Honet LC, Parente MG, Woodley DT, Pan TC, Zhang RZ, Chu ML, Burgeson RE, Uitto J: The large non-collagenous domain (NC-1) of type VII collagen is amino-terminal and chimeric: homology to cartilage matrix protein, the type III domains of fibronectin and the A domains of von Willebrand factor. Hum Mol Genet. 1992, 1: 475-481. 10.1093/hmg/1.7.475.PubMedCrossRef
12.
Greenspan DS: The carboxyl-terminal half of type VII collagen, including the non-collagenous NC-2 domain and intron⁄exon organization of the corresponding region of the COL7A1 gene. Hum Mol Genet. 1993, 2: 273-278. 10.1093/hmg/2.3.273.PubMedCrossRef
13.
14.
15.
Sitaru AG, Sesarman A, Mihai S, Chiriac MT, Zillikens D, Hultman P, Solbach W, Sitaru C: T cells are required for the production of blister-inducing autoantibodies in experimental epidermolysis bullosa acquisita. J Immunol. 2010, 184: 1596-1603. 10.4049/jimmunol.0901412.PubMedCrossRef
16.
Woodley DT, Briggaman RA, O'Keefe EJ, Inman AO, Queen LL, Gammon WR: Identification of the skin basement-membrane autoantigen in epidermolysis bullosa acquisita. N Engl J Med. 1984, 310: 1007-1013. 10.1056/NEJM198404193101602.PubMedCrossRef
17.
Tanaka H, Ishida-Yamamoto A, Hashimoto T, Hiramoto K, Harada T, Kawachi Y, Shimizu H, Tanaka T, Kishiyama K, Höpfner B, Takahashi H, Iizuka H, Bruckner-Tuderman L: A novel variant of acquired epidermolysis bullosa with autoantibodies against the central triple-helical domain of type VII collagen. Lab Invest. 1997, 77: 623-632.PubMed
18.
Müller R, Dahler C, Möbs C, Wenzel E, Eming R, Messer G, Niedermeier A, Hertl M: T and B cells target identical regions of the non-collagenous domain 1 of type VII collagen in epidermolysis bullosa acquisita. Clin Immunol. 2010, 135: 99-107. 10.1016/j.clim.2009.12.010.PubMedCrossRef
19.
Schmidt E, Zillikens D: Modern diagnosis of autoimmune blistering skin diseases. Autoimmun Rev. 2010, 10: 84-89. 10.1016/j.autrev.2010.08.007.PubMedCrossRef
20.
Saleh MA, Ishii K, Kim YJ, Murakami A, Ishii N, Hashimoto T, Schmidt E, Zillikens D, Shirakata Y, Hashimoto K, Kitajima Y, Amagai M: Development of NC-1 and NC-2 domains of Type VII collagen ELISA for the diagnosis and analysis of the time course of epidermolysis bullosa acquisita patients. J Dermatol Sci. 2011, 62: 169-175. 10.1016/j.jdermsci.2011.03.003.PubMedCrossRef
21.
Komorowski L, Müller R, Vorobyev A, Probst C, Recke A, Jonkman MF, Hashimoto T, Kim SC, Groves R, Ludwig RJ, Zillikens D, Stöcker W, Schmidt E: Sensitive and specific assays for routine serological diagnosis of epidermolysis bullosa acquisita. J Am Acad Dermatol. 2013, 68: e89-e95. 10.1016/j.jaad.2011.12.032.PubMedCrossRef
22.
Sato M, Ishitsuka A, Shibuya Y, Kanoh H, Koga H, Hashimoto T, Seishima M: Time-course of the change in titre of antibodies against type VII collagen in a patient with epidermolysis bullosa acquisita. Acta Derm Venereol. 2012, 92: 693-694. 10.2340/00015555-1339.PubMedCrossRef
23.
Marzano AV, Cozzani E, Fanoni D, De Pità O, Vassallo C, Berti E, Parodi A, Crosti C, Cugno M: Diagnosis and disease severity assessment of epidermolysis bullosa acquisita by ELISA for anti-type VII collagen autoantibodies: an Italian multicentre study. Br J Dermatol. 2013, 168: 80-84. 10.1111/bjd.12011.PubMedCrossRef
24.
Kim JH, Kim YH, Kim S, Noh EB, Kim SE, Vorobyev A, Schmidt E, Zillikens D, Kim SC: Serum levels of anti-type VII collagen antibodies detected by enzyme-linked immunosorbent assay in patients with epidermolysis bullosa acquisita are correlated with the severity of skin lesions. J Eur Acad Dermatol Venereol. 2013, 27: e224-e230. 10.1111/j.1468-3083.2012.04617.x.PubMedCrossRef
25.
Sitaru C, Mihai S, Otto C, Chiriac MT, Hausser I, Dotterweich B, Saito H, Rose C, Ishiko A, Zillikens D: Induction of dermal-epidermal separation in mice by passive transfer of antibodies specific to type VII collagen. J Clin Invest. 2005, 115: 870-878.PubMedCentralPubMedCrossRef
26.
Woodley DT, Ram R, Doostan A, Bandyopadhyay P, Huang Y, Remington J, Hou Y, Keene DR, Liu Z, Chen M: Induction of epidermolysis bullosa acquisita in mice by passive transfer of autoantibodies from patients. J Invest Dermatol. 2006, 126: 1323-1330. 10.1038/sj.jid.5700254.PubMedCrossRef
27.
Ludwig RJ, Recke A, Bieber K, Müller S, Marques Ade C, Banczyk D, Hirose M, Kasperkiewicz M, Ishii N, Schmidt E, Westermann J, Zillikens D, Ibrahim SM: Generation of antibodies of distinct subclasses and specificity is linked to H2s in an active mouse model of epidermolysis bullosa acquisita. J Invest Dermatol. 2011, 131: 167-176. 10.1038/jid.2010.248.PubMedCrossRef
28.
Moss C, Wong A, Davies P: The Birmingham Epidermolysis Bullosa Severity score: development and validation. Br J Dermatol. 2009, 160: 1057-1065. 10.1111/j.1365-2133.2009.09041.x.PubMedCrossRef
29.
Chen M, Kim GH, Prakash L, Woodley DT: Epidermolysis bullosa acquisita: autoimmunity to anchoring fibril collagen. Autoimmunity. 2012, 45: 91-101. 10.3109/08916934.2011.606450.PubMedCentralPubMedCrossRef
30.
Sesarman A, Sitaru C: Induction of experimental epidermolysis bullosa acquisita by immunization with murine collagen VII. Meth Mol Biol. 2013, 961: 371-387. 10.1007/978-1-62703-227-8_25.CrossRef
31.
32.
Cusick MF, Libbey JE, Fujinami RS: Molecular mimicry as a mechanism of autoimmune disease. Clin Rev Allergy Immunol. 2012, 42: 102-111. 10.1007/s12016-011-8294-7.PubMedCentralPubMedCrossRef
33.
Hundorfean G, Neurath MF, Sitaru C: Autoimmunity against type VII collagen in inflammatory bowel disease. J Cell Mol Med. 2010, 14: 2393-2403. 10.1111/j.1582-4934.2009.00959.x.PubMedCentralPubMedCrossRef
34.
Licarete E, Ganz S, Recknagel MJ, Di Zenzo G, Hashimoto T, Hertl M, Zambruno G, Hundorfean G, Mudter J, Neurath MF, Bruckner-Tuderman L, Sitaru C: Prevalence of collagen VII-specific autoantibodies in patients with autoimmune and inflammatory diseases. BMC Immunol. 2012, 13: 16-10.1186/1471-2172-13-16.PubMedCentralPubMedCrossRef
35.
Mihai S, Chiriac MT, Herrero-González JE, Goodall M, Jefferis R, Savage CO, Zillikens D, Sitaru C: IgG4 autoantibodies induce dermal-epidermal separation. J Cell Mol Med. 2007, 11: 1117-1128. 10.1111/j.1582-4934.2007.00081.x.PubMedCentralPubMedCrossRef
36.
Di Zenzo G, Thoma-Uszynski S, Calabresi V, Fontao L, Hofmann SC, Lacour JP, Sera F, Bruckner-Tuderman L, Zambruno G, Borradori L, Hertl M: Demonstration of epitope e-spreading phenomena in bullous pemphigoid: results of a prospective multicenter study. J Invest Dermatol. 2011, 131: 2271-2280. 10.1038/jid.2011.180.PubMedCrossRef
37.
Tamai K, Hashimoto I, Hanada K, Ikeda S, Imamura S, Ogawa H: Japanese Study Group for Rare Intractable Skin Diseases: Japanese guidelines for diagnosis and treatment of junctional and dystrophic epidermolysis bullosa. Arch Dermatol Res. 2003, 295: S24-S28.PubMed
38.
Fortuna G, Chainani-Wu N, Lozada-Nur F, Aria M, Cepeda-Valdes R, Pollio A, Marinkovich MP, Martinez-Salazar AE, Mignogna MD, Bruckner AL, Salas-Alanís JC: Epidermolysis Bullosa Oropharyngeal Severity (EBOS) score: a multicenter development and reliability assessment. J Am Acad Dermatol. 2013, 68: 83-92. 10.1016/j.jaad.2012.04.009.PubMedCrossRef
39.
Loh CH, Kim J, Su JC, Daniel BS, Venugopal SS, Rhodes LM, Intong L, Law M, Murrell DF: Excellent reliability and validity of a novel Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI) compared to two other outcome measures. J Investig Dermatol. 2013, 133 (S1): 518.
Metadata
Title
Prevalence of specific anti-skin autoantibodies in a cohort of patients with inherited epidermolysis bullosa
Authors
Marilina Tampoia
Domenico Bonamonte
Angela Filoni
Lucrezia Garofalo
Maria Grazia Morgese
Luigia Brunetti
Chiara Di Giorgio
Giuseppina Annicchiarico
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Orphanet Journal of Rare Diseases / Issue 1/2013
Electronic ISSN: 1750-1172
DOI
https://doi.org/10.1186/1750-1172-8-132

Other articles of this Issue 1/2013

Orphanet Journal of Rare Diseases 1/2013 Go to the issue

Research

Haploidentical stem cell transplantation in two children with mucopolysaccharidosis VI: clinical and biochemical outcome

Research

The effects of Eculizumab on the pathology of malignant atrophic papulosis

Research

Development and validation of COMPASS: clinical evidence of orphan medicinal products – an assessment tool

Review

A clinical and molecular review of ubiquitous glucose-6-phosphatase deficiency caused by G6PC3mutations

Research

New clinical and molecular insights on Barth syndrome

Research

MRI characterisation of adult onset alpha-methylacyl-coA racemase deficiency diagnosed by exome sequencing